<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39434774</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Decoding the intricacies: a comprehensive analysis of microRNAs in the pathogenesis, diagnosis, prognosis and therapeutic strategies for COVID-19.</ArticleTitle><Pagination><StartPage>1430974</StartPage><MedlinePgn>1430974</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1430974</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2024.1430974</ELocationID><Abstract><AbstractText>The pandemic of coronavirus disease-19 (COVID-19), provoked by the appearance of a novel coronavirus named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), required a worldwide healthcare emergency. This has elicited an immediate need for accelerated research into its mechanisms of disease, criteria for diagnosis, methods for forecasting outcomes, and treatment approaches. microRNAs (miRNAs), are diminutive RNA molecules, that are non-coding and participate in gene expression regulation post-transcriptionally, having an important participation in regulating immune processes. miRNAs have granted substantial interest in their impact on viral replication, cell proliferation, and modulation of how the host's immune system responds. This narrative review delves into host miRNAs' multifaceted roles within the COVID-19 context, highlighting their involvement in disease progression, diagnostics, and prognostics aspects, given their stability in biological fluids and varied expression profiles when responding to an infection. Additionally, we discuss complicated interactions between SARS-CoV-2 and host cellular machinery facilitated by host miRNAs revealing how dysregulation of host miRNA expression profiles advances viral replication, immune evasion, and inflammatory responses. Furthermore, it investigates the potential of host miRNAs as therapeutic agents, whether synthetic or naturally occurring, which could be harnessed to either mitigate harmful inflammation or enhance antiviral responses. However, searching more deeply is needed to clarify how host's miRNAs are involved in pathogenesis of COVID-19, its diagnosis processes, prognostic assessments, and treatment approaches for patients.</AbstractText><CopyrightInformation>Copyright © 2024 Smail, Hirmiz, Ahmed, Albarzinji, Awla, Amin and Janson.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Smail</LastName><ForeName>Shukur Wasman</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Cihan University-Erbil, Kurdistan Region, Erbil, Iraq.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biology, College of Science, Salahaddin University-Erbil, Erbil, Iraq.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirmiz</LastName><ForeName>Sarah Mousa</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Biology, College of Science, Salahaddin University-Erbil, Erbil, Iraq.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Akhter Ahmed</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Biology, College of Science, Salahaddin University-Erbil, Erbil, Iraq.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albarzinji</LastName><ForeName>Niaz</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medicine, Hawler Medical University, Erbil, Iraq.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Awla</LastName><ForeName>Harem Khdir</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Department of Biology, College of Science, Salahaddin University-Erbil, Erbil, Iraq.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amin</LastName><ForeName>Kawa</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>College of Medicine, University of Sulaimani, Sulaymaniyah, Iraq.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janson</LastName><ForeName>Christer</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">microRNAs</Keyword><Keyword MajorTopicYN="N">therapeutic strategies</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>4</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39434774</ArticleId><ArticleId IdType="pmc">PMC11492531</ArticleId><ArticleId IdType="doi">10.3389/fmed.2024.1430974</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Roustai Geraylow K, Hemmati R, Kadkhoda S, Ghafouri-Fard S. miRNA expression in COVID-19. Gene Rep. (2022) 28:101641. doi: 10.1016/j.genrep.2022.101641, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genrep.2022.101641</ArticleId><ArticleId IdType="pmc">PMC9288248</ArticleId><ArticleId IdType="pubmed">35875722</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Amahong K, Sun X, Lian X, Liu J, Sun H, et al. . The miRNA: a small but powerful RNA for COVID-19. Brief Bioinform. (2021) 22:1137–49. doi: 10.1093/bib/bbab062, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbab062</ArticleId><ArticleId IdType="pmc">PMC7989616</ArticleId><ArticleId IdType="pubmed">33675361</ArticleId></ArticleIdList></Reference><Reference><Citation>Abedi F, Rezaee R, Hayes AW, Nasiripour S, Karimi G. MicroRNAs and SARS-CoV-2 life cycle, pathogenesis, and mutations: biomarkers or therapeutic agents? Cell Cycle. (2021) 20:143–53. doi: 10.1080/15384101.2020.1867792, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15384101.2020.1867792</ArticleId><ArticleId IdType="pmc">PMC7889196</ArticleId><ArticleId IdType="pubmed">33382348</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes-Long S, Cortes-Altamirano JL, Bandala C, Avendano-Ortiz K, Bonilla-Jaime H, Bueno-Nava A, et al. . Role of the microRNAs in the pathogenic mechanism of painful symptoms in long COVID: systematic review. Int J Mol Sci. (2023) 24:3574. doi: 10.3390/ijms24043574, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24043574</ArticleId><ArticleId IdType="pmc">PMC9963913</ArticleId><ArticleId IdType="pubmed">36834984</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrew W, Meizi Y, DaLiao X. Therapeutic implication of miRNA in human disease In: Shashwat S, Suman K, editors. Antisense therapy. Rijeka: IntechOpen; (2018). 6.</Citation></Reference><Reference><Citation>Notarte KI, Senanayake S, Macaranas I, Albano PM, Mundo L, Fennell E, et al. . MicroRNA and other non-coding RNAs in Epstein–Barr virus-associated cancers. Cancers. (2021) 13:3909. doi: 10.3390/cancers13153909</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13153909</ArticleId><ArticleId IdType="pmc">PMC8345394</ArticleId><ArticleId IdType="pubmed">34359809</ArticleId></ArticleIdList></Reference><Reference><Citation>Bivona G, Agnello L, Ciaccio M. Biomarkers for prognosis and treatment response in COVID-19 patients. Ann Lab Med. (2021) 41:540–8. doi: 10.3343/alm.2021.41.6.540, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3343/alm.2021.41.6.540</ArticleId><ArticleId IdType="pmc">PMC8203437</ArticleId><ArticleId IdType="pubmed">34108281</ArticleId></ArticleIdList></Reference><Reference><Citation>Guterres A, de Azeredo Lima CH, Miranda RL, Gadelha MR. What is the potential function of microRNAs as biomarkers and therapeutic targets in COVID-19? Infect Genet Evol. (2020) 85:104417. doi: 10.1016/j.meegid.2020.104417, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2020.104417</ArticleId><ArticleId IdType="pmc">PMC7833518</ArticleId><ArticleId IdType="pubmed">32526370</ArticleId></ArticleIdList></Reference><Reference><Citation>Donyavi T, Bokharaei-Salim F, Baghi HB, Khanaliha K, Alaei Janat-Makan M, Karimi B, et al. . Acute and post-acute phase of COVID-19: analyzing expression patterns of miRNA-29a-3p, 146a-3p, 155-5p, and let-7b-3p in PBMC. Int Immunopharmacol. (2021) 97:107641. doi: 10.1016/j.intimp.2021.107641, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.107641</ArticleId><ArticleId IdType="pmc">PMC8023203</ArticleId><ArticleId IdType="pubmed">33895478</ArticleId></ArticleIdList></Reference><Reference><Citation>Farr RJ, Rootes CL, Rowntree LC, Nguyen THO, Hensen L, Kedzierski L, et al. . Altered microRNA expression in COVID-19 patients enables identification of SARS-CoV-2 infection. PLoS Pathog. (2021) 17:e1009759. doi: 10.1371/journal.ppat.1009759, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009759</ArticleId><ArticleId IdType="pmc">PMC8318295</ArticleId><ArticleId IdType="pubmed">34320031</ArticleId></ArticleIdList></Reference><Reference><Citation>Gedikbasi A, Adas G, Isiksacan N, Kart Yasar K, Canbolat Unlu E, Yilmaz R, et al. . The effect of host miRNAs on prognosis in COVID-19: miRNA-155 may promote severity via targeting suppressor of cytokine signaling 1 (SOCS1) gene. Genes. (2022) 13:1146. doi: 10.3390/genes13071146</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes13071146</ArticleId><ArticleId IdType="pmc">PMC9320261</ArticleId><ArticleId IdType="pubmed">35885930</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. . Treatment of HCV infection by targeting microRNA. N Engl J Med. (2013) 368:1685–94. doi: 10.1056/NEJMoa1209026</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1209026</ArticleId><ArticleId IdType="pubmed">23534542</ArticleId></ArticleIdList></Reference><Reference><Citation>Girardi E, López P, Pfeffer S. On the importance of host microRNAs during viral infection. Front Genet. (2018) 9:439. doi: 10.3389/fgene.2018.00439, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2018.00439</ArticleId><ArticleId IdType="pmc">PMC6176045</ArticleId><ArticleId IdType="pubmed">30333857</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartel DP. Metazoan MicroRNAs. Cell. (2018) 173:20–51. doi: 10.1016/j.cell.2018.03.006, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.006</ArticleId><ArticleId IdType="pmc">PMC6091663</ArticleId><ArticleId IdType="pubmed">29570994</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhdanov VP. Intracellular miRNA or siRNA delivery and function. Biosystems. (2018) 171:20–5. doi: 10.1016/j.biosystems.2018.05.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biosystems.2018.05.007</ArticleId><ArticleId IdType="pubmed">29859208</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan N, Jaggi M, Chauhan SC, Yallapu MM. COVID-19: fighting the invisible enemy with microRNAs. Expert Rev Anti-Infect Ther. (2021) 19:137–45. doi: 10.1080/14787210.2020.1812385, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14787210.2020.1812385</ArticleId><ArticleId IdType="pmc">PMC7870525</ArticleId><ArticleId IdType="pubmed">32814446</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebolledo-Mendez JD, Vaishnav RA, Cooper NG, Friedland RP. Cross-kingdom sequence similarities between human micro-RNAs and plant viruses. Commun Integr Biol. (2013) 6:e24951. doi: 10.4161/cib.24951, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/cib.24951</ArticleId><ArticleId IdType="pmc">PMC3821693</ArticleId><ArticleId IdType="pubmed">24228136</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. (2021) 19:141–54. doi: 10.1038/s41579-020-00459-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00459-7</ArticleId><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. (2019) 17:181–92. doi: 10.1038/s41579-018-0118-9, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0118-9</ArticleId><ArticleId IdType="pmc">PMC7097006</ArticleId><ArticleId IdType="pubmed">30531947</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhama K, Patel SK, Sharun K, Pathak M, Tiwari R, Yatoo MI, et al. . SARS-CoV-2 jumping the species barrier: zoonotic lessons from SARS, MERS and recent advances to combat this pandemic virus. Travel Med Infect Dis. (2020) 37:101830. doi: 10.1016/j.tmaid.2020.101830, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2020.101830</ArticleId><ArticleId IdType="pmc">PMC7396141</ArticleId><ArticleId IdType="pubmed">32755673</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui DS, IA E, Madani TA, Ntoumi F, Kock R, Dar O, et al. . The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. (2020) 91:264–6. doi: 10.1016/j.ijid.2020.01.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.01.009</ArticleId><ArticleId IdType="pmc">PMC7128332</ArticleId><ArticleId IdType="pubmed">31953166</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Rao Z. Structural biology of SARS-CoV-2 and implications for therapeutic development. Nat Rev Microbiol. (2021) 19:685–700. doi: 10.1038/s41579-021-00630-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00630-8</ArticleId><ArticleId IdType="pmc">PMC8447893</ArticleId><ArticleId IdType="pubmed">34535791</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM. SARS-CoV-2: structure, biology, and structure-based therapeutics development. Front Cell Infect Microbiol. (2020) 10:587269. doi: 10.3389/fcimb.2020.587269, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2020.587269</ArticleId><ArticleId IdType="pmc">PMC7723891</ArticleId><ArticleId IdType="pubmed">33324574</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu W, Cheng Y, Zhou H, Sun C, Zhang S. The SARS-CoV-2 nucleocapsid protein: its role in the viral life cycle, structure and functions, and use as a potential target in the development of vaccines and diagnostics. Virol J. (2023) 20:6. doi: 10.1186/s12985-023-01968-6, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-023-01968-6</ArticleId><ArticleId IdType="pmc">PMC9831023</ArticleId><ArticleId IdType="pubmed">36627683</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). Treasure Island, FL: StatPearls; (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">32150360</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee S, Wang X, Du S, Zhu C, Jia Y, Wang Y, et al. . Comprehensive role of SARS-CoV-2 spike glycoprotein in regulating host signaling pathway. J Med Virol. (2022) 94:4071–87. doi: 10.1002/jmv.27820, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27820</ArticleId><ArticleId IdType="pmc">PMC9348444</ArticleId><ArticleId IdType="pubmed">35488404</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas S. The structure of the membrane protein of SARS-CoV-2 resembles the sugar transporter SemiSWEET. Pathog Immun. (2020) 5:342–63. doi: 10.20411/pai.v5i1.377, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.20411/pai.v5i1.377</ArticleId><ArticleId IdType="pmc">PMC7608487</ArticleId><ArticleId IdType="pubmed">33154981</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Yang R, Lee I, Zhang W, Sun J, Wang W, et al. . Characterization of the SARS-CoV-2 E protein: sequence, structure, viroporin, and inhibitors. Protein Sci. (2021) 30:1114–30. doi: 10.1002/pro.4075</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.4075</ArticleId><ArticleId IdType="pmc">PMC8138525</ArticleId><ArticleId IdType="pubmed">33813796</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos-Mendoza T. The envelope (E) protein of SARS-CoV-2 as a pharmacological target. Viruses. (2023) 15:1000. doi: 10.3390/v15041000, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15041000</ArticleId><ArticleId IdType="pmc">PMC10143767</ArticleId><ArticleId IdType="pubmed">37112980</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 transmission and pathogenesis. Trends Immunol. (2020) 41:1100–15. doi: 10.1016/j.it.2020.10.004, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2020.10.004</ArticleId><ArticleId IdType="pmc">PMC7556779</ArticleId><ArticleId IdType="pubmed">33132005</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. (2004) 203:631–7. doi: 10.1002/path.1570, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.1570</ArticleId><ArticleId IdType="pmc">PMC7167720</ArticleId><ArticleId IdType="pubmed">15141377</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu KH, Tsang WK, Tang CS, Lam MF, Lai FM, To KF, et al. . Acute renal impairment in coronavirus-associated severe acute respiratory syndrome. Kidney Int. (2005) 67:698–705. doi: 10.1111/j.1523-1755.2005.67130.x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1523-1755.2005.67130.x</ArticleId><ArticleId IdType="pmc">PMC7112337</ArticleId><ArticleId IdType="pubmed">15673319</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YZ, Liu G, Senju S, Wang Q, Irie A, Haruta M, et al. . Identification of SARS-COV spike protein-derived and HLA-A2-restricted human CTL epitopes by using a new muramyl dipeptidederivative adjuvant. Int J Immunopathol Pharmacol. (2010) 23:165–77. doi: 10.1177/039463201002300115, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/039463201002300115</ArticleId><ArticleId IdType="pubmed">20378004</ArticleId></ArticleIdList></Reference><Reference><Citation>Fast E, Altman RB, Chen B. (2020). Potential T-cell and B-cell epitopes of 2019-nCoV. bioRxiv. Available at: 10.1101/2020.02.19.955484. [Epub ahead of preprint]</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.02.19.955484</ArticleId></ArticleIdList></Reference><Reference><Citation>Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. (2020) 38:1–9. doi: 10.12932/AP-200220-0772, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.12932/AP-200220-0772</ArticleId><ArticleId IdType="pubmed">32105090</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan L, Karimi N, Morovati S, Alizadeh K, Kakish JE, Vanderkamp S, et al. . The roles of neutrophils in cytokine storms. Viruses. (2021) 13:2318. doi: 10.3390/v13112318, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13112318</ArticleId><ArticleId IdType="pmc">PMC8624379</ArticleId><ArticleId IdType="pubmed">34835125</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenmann M, Stoddart MJ, Schmelzeisen R, Gross C, Della Bella E, Rothweiler RM. Basic principles of RNA interference: nucleic acid types and in vitro intracellular delivery methods. Micromachines. (2023) 14:1321. doi: 10.3390/mi14071321</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/mi14071321</ArticleId><ArticleId IdType="pmc">PMC10383872</ArticleId><ArticleId IdType="pubmed">37512632</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Y, Fang D, Gao X, Deng X, Chen N, Wu J, et al. . Circulating microRNAs as emerging regulators of COVID-19. Theranostics. (2023) 13:125–47. doi: 10.7150/thno.78164, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.78164</ArticleId><ArticleId IdType="pmc">PMC9800721</ArticleId><ArticleId IdType="pubmed">36593971</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocchi A, Chiti E, Maiese A, Turillazzi E, Spinetti I. MicroRNAs: an update of applications in forensic science. Diagnostics. (2020) 11:32. doi: 10.3390/diagnostics11010032</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics11010032</ArticleId><ArticleId IdType="pmc">PMC7823886</ArticleId><ArticleId IdType="pubmed">33375374</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiman-Shimony A, Shtrikman O, Margalit H. Assessing the functional association of intronic miRNAs with their host genes. RNA. (2018) 24:991–1004. doi: 10.1261/rna.064386.117, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1261/rna.064386.117</ArticleId><ArticleId IdType="pmc">PMC6049507</ArticleId><ArticleId IdType="pubmed">29752351</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorge AL, Pereira ER, Oliveira CS, Ferreira EDS, Menon ETN, Diniz SN, et al. . MicroRNAs: understanding their role in gene expression and cancer. Einstein. (2021) 19:eRB5996. doi: 10.31744/einstein_journal/2021RB5996, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.31744/einstein_journal/2021RB5996</ArticleId><ArticleId IdType="pmc">PMC8277234</ArticleId><ArticleId IdType="pubmed">34287566</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang HY, Lin YC, Li J, Huang KY, Shrestha S, Hong HC, et al. . miRTarBase 2020: updates to the experimentally validated microRNA-target interaction database. Nucleic Acids Res. (2020) 48:D148–54. doi: 10.1093/nar/gkz896</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz896</ArticleId><ArticleId IdType="pmc">PMC7145596</ArticleId><ArticleId IdType="pubmed">31647101</ArticleId></ArticleIdList></Reference><Reference><Citation>Dharap A, Pokrzywa C, Murali S, Pandi G, Vemuganti R. MicroRNA miR-324-3p induces promoter-mediated expression of RelA gene. PLoS One. (2013) 8:e79467. doi: 10.1371/journal.pone.0079467, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0079467</ArticleId><ArticleId IdType="pmc">PMC3827167</ArticleId><ArticleId IdType="pubmed">24265774</ArticleId></ArticleIdList></Reference><Reference><Citation>Daka A, Peer D. RNAi-based nanomedicines for targeted personalized therapy. Adv Drug Deliv Rev. (2012) 64:1508–21. doi: 10.1016/j.addr.2012.08.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2012.08.014</ArticleId><ArticleId IdType="pubmed">22975009</ArticleId></ArticleIdList></Reference><Reference><Citation>Trobaugh DW, Klimstra WB. MicroRNA regulation of RNA virus replication and pathogenesis. Trends Mol Med. (2017) 23:80–93. doi: 10.1016/j.molmed.2016.11.003, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2016.11.003</ArticleId><ArticleId IdType="pmc">PMC5836316</ArticleId><ArticleId IdType="pubmed">27989642</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparello J, Finotti A, Gambari R. Tackling the COVID-19 “cytokine storm” with microRNA mimics directly targeting the 3’UTR of pro-inflammatory mRNAs. Med Hypotheses. (2021) 146:110415. doi: 10.1016/j.mehy.2020.110415</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.110415</ArticleId><ArticleId IdType="pmc">PMC7685948</ArticleId><ArticleId IdType="pubmed">33422363</ArticleId></ArticleIdList></Reference><Reference><Citation>Ergun S, Sankaranarayanan R, Petrovic N. Clinically informative microRNAs for SARS-CoV-2 infection. Epigenomics. (2023) 15:705–16. doi: 10.2217/epi-2023-0179, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/epi-2023-0179</ArticleId><ArticleId IdType="pmc">PMC10476648</ArticleId><ArticleId IdType="pubmed">37661862</ArticleId></ArticleIdList></Reference><Reference><Citation>Maranini B, Ciancio G, Ferracin M, Cultrera R, Negrini M, Sabbioni S, et al. . microRNAs and inflammatory immune response in SARS-CoV-2 infection: a narrative review. Life. (2022) 12:288. doi: 10.3390/life12020288</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life12020288</ArticleId><ArticleId IdType="pmc">PMC8879390</ArticleId><ArticleId IdType="pubmed">35207576</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang K, Yang J, Guo S, Zhao G, Wu H, Deng G. Peripheral circulating exosome-mediated delivery of miR-155 as a novel mechanism for acute lung inflammation. Mol Ther. (2019) 27:1758–71. doi: 10.1016/j.ymthe.2019.07.003, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2019.07.003</ArticleId><ArticleId IdType="pmc">PMC6822235</ArticleId><ArticleId IdType="pubmed">31405809</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol. (2007) 7:454–65. doi: 10.1038/nri2093</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2093</ArticleId><ArticleId IdType="pubmed">17525754</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu R, Zhang Y, Yang X, Yan J, Sun Y, Chen Z, et al. . Isoflurane attenuates LPS-induced acute lung injury by targeting miR-155-HIF1-alpha. Front Biosci. (2015) 20:139–56. doi: 10.2741/4302, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/4302</ArticleId><ArticleId IdType="pubmed">25553444</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu L, Zhu P, Qi S, Li C, Zhao K. MicroRNA-92a antagonism attenuates lipopolysaccharide (LPS)-induced pulmonary inflammation and injury in mice through suppressing the PTEN/AKT/NF-κB signaling pathway. Biomed Pharmacother. (2018) 107:703–11. doi: 10.1016/j.biopha.2018.08.040, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2018.08.040</ArticleId><ArticleId IdType="pubmed">30138892</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun C-M, Wu J, Zhang H, Shi G, Chen Z-T. Circulating miR-125a but not miR-125b is decreased in active disease status and negatively correlates with disease severity as well as inflammatory cytokines in patients with Crohn’s disease. World J Gastroenterol. (2017) 23:7888–98. doi: 10.3748/wjg.v23.i44.7888, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v23.i44.7888</ArticleId><ArticleId IdType="pmc">PMC5703918</ArticleId><ArticleId IdType="pubmed">29209130</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaz CO, Hounkpe BW, Oliveira JD, Mazetto B, Cardoso Jacintho B, Aparecida Locachevic G, et al. . MicroRNA 205-5p and COVID-19 adverse outcomes: potential molecular biomarker and regulator of the immune response. Exp Biol Med. (2023) 248:1024–33. doi: 10.1177/15353702231175412, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/15353702231175412</ArticleId><ArticleId IdType="pmc">PMC10323515</ArticleId><ArticleId IdType="pubmed">37403291</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Lin S, Tang Q, Yan Z. Knockdown of miR-205-5p alleviates the inflammatory response in allergic rhinitis by targeting B-cell lymphoma 6. Mol Med Rep. (2021) 24:818. doi: 10.3892/mmr.2021.12458, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2021.12458</ArticleId><ArticleId IdType="pmc">PMC8477609</ArticleId><ArticleId IdType="pubmed">34558634</ArticleId></ArticleIdList></Reference><Reference><Citation>Sánchez MY, Santos MM, Oltra M, dos Santos Pires ME, Sancho-Pelluz J, Barcia JM. Regulation of HIF-1α/VEGFA mRNA transcription by miR-205-5p in diabetic mice. Invest Ophthalmol Vis Sci. (2024) 65:842.</Citation></Reference><Reference><Citation>Gjorgjieva T, Chaloemtoem A, Shahin T, Bayaraa O, Dieng MM, Alshaikh M, et al. . Systems genetics identifies miRNA-mediated regulation of host response in COVID-19. Hum Genomics. (2023) 17:49. doi: 10.1186/s40246-023-00494-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40246-023-00494-4</ArticleId><ArticleId IdType="pmc">PMC10257974</ArticleId><ArticleId IdType="pubmed">37303042</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Liu H, Hu Q, Wang J, Zhang S, Cui W, et al. . Astrocyte-derived extracellular vesicular miR-143-3p dampens autophagic degradation of endothelial adhesion molecules and promotes neutrophil transendothelial migration after acute brain injury. Adv Sci. (2024) 11:2305339. doi: 10.1002/advs.202305339</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202305339</ArticleId><ArticleId IdType="pmc">PMC10837358</ArticleId><ArticleId IdType="pubmed">38044319</ArticleId></ArticleIdList></Reference><Reference><Citation>Vier J, Groth M, Sochalska M, Kirschnek S. The anti-apoptotic Bcl-2 family protein A1/Bfl-1 regulates neutrophil survival and homeostasis and is controlled via PI3K and JAK/STAT signaling. Cell Death Dis. (2016) 7:e2103. doi: 10.1038/cddis.2016.23</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2016.23</ArticleId><ArticleId IdType="pmc">PMC5399193</ArticleId><ArticleId IdType="pubmed">26890142</ArticleId></ArticleIdList></Reference><Reference><Citation>Locke FL, Zha Y-y, Zheng Y, Driessens G, Gajewski TF. Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction. J Immunol. (2013) 191:1677–85. doi: 10.4049/jimmunol.1202018, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1202018</ArticleId><ArticleId IdType="pmc">PMC3759681</ArticleId><ArticleId IdType="pubmed">23851688</ArticleId></ArticleIdList></Reference><Reference><Citation>Gracias DT, Stelekati E, Hope JL, Boesteanu AC, Doering TA, Norton J, et al. . The microRNA miR-155 controls CD8+ T cell responses by regulating interferon signaling. Nat Immunol. (2013) 14:593–602. doi: 10.1038/ni.2576</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2576</ArticleId><ArticleId IdType="pmc">PMC3664306</ArticleId><ArticleId IdType="pubmed">23603793</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C-H, Chen D-X, Dong K, Wu Y-J, Na N, Wen H, et al. . Inhibition of miR-143-3p alleviates myocardial ischemia reperfusion injury via limiting mitochondria-mediated apoptosis. Biol Chem. (2023) 404:619–31. doi: 10.1515/hsz-2022-0334</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/hsz-2022-0334</ArticleId><ArticleId IdType="pubmed">36780323</ArticleId></ArticleIdList></Reference><Reference><Citation>Seddiki N, Brezar V, Ruffin N, Lévy Y, Swaminathan S. Role of miR-155 in the regulation of lymphocyte immune function and disease. Immunology. (2014) 142:32–8. doi: 10.1111/imm.12227, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.12227</ArticleId><ArticleId IdType="pmc">PMC3992045</ArticleId><ArticleId IdType="pubmed">24303979</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang CY, Chen YH, Liu PJ, Hu WC, Lu KC, Tsai KW. The emerging role of miRNAs in the pathogenesis of COVID-19: protective effects of nutraceutical polyphenolic compounds against SARS-CoV-2 infection. Int J Med Sci. (2022) 19:1340–56. doi: 10.7150/ijms.76168, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.76168</ArticleId><ArticleId IdType="pmc">PMC9346380</ArticleId><ArticleId IdType="pubmed">35928726</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanmohammadi S, Rezaei N. Role of toll-like receptors in the pathogenesis of COVID-19. J Med Virol. (2021) 93:2735–9. doi: 10.1002/jmv.26826, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26826</ArticleId><ArticleId IdType="pmc">PMC8014260</ArticleId><ArticleId IdType="pubmed">33506952</ArticleId></ArticleIdList></Reference><Reference><Citation>Roganovic J. Downregulation of microRNA-146a in diabetes, obesity and hypertension may contribute to severe COVID-19. Med Hypotheses. (2021) 146:110448. doi: 10.1016/j.mehy.2020.110448</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.110448</ArticleId><ArticleId IdType="pmc">PMC7836676</ArticleId><ArticleId IdType="pubmed">33338955</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankovic M, Nikolic D, Novakovic I, Petrovic B, Lackovic M, Santric-Milicevic M. miRNAs as a potential biomarker in the COVID-19 infection and complications course, severity, and outcome. Diagnostics. (2023) 13:1091. doi: 10.3390/diagnostics13061091</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics13061091</ArticleId><ArticleId IdType="pmc">PMC10047241</ArticleId><ArticleId IdType="pubmed">36980399</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Zhu X, Jiang XM, Guo J, Fu Z, Zhou Z, et al. . Decreased inhibition of exosomal miRNAs on SARS-CoV-2 replication underlies poor outcomes in elderly people and diabetic patients. Signal Transduct Target Ther. (2021) 6:300. doi: 10.1038/s41392-021-00716-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00716-y</ArticleId><ArticleId IdType="pmc">PMC8355568</ArticleId><ArticleId IdType="pubmed">34381015</ArticleId></ArticleIdList></Reference><Reference><Citation>Shukuya T, Ghai V, Amann JM, Okimoto T, Shilo K, Kim TK, et al. . Circulating microRNAs and extracellular vesicle-containing microRNAs as response biomarkers of anti-programmed cell death protein 1 or programmed death-ligand 1 therapy in NSCLC. J Thorac Oncol. (2020) 15:1773–81. doi: 10.1016/j.jtho.2020.05.022, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtho.2020.05.022</ArticleId><ArticleId IdType="pmc">PMC7641981</ArticleId><ArticleId IdType="pubmed">32565389</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozniak T, Shcharbin D, Bryszewska M. Circulating microRNAs in medicine. Int J Mol Sci. (2022) 23:3996. doi: 10.3390/ijms23073996</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23073996</ArticleId><ArticleId IdType="pmc">PMC8999557</ArticleId><ArticleId IdType="pubmed">35409354</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol. (2018) 9:402. doi: 10.3389/fendo.2018.00402, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2018.00402</ArticleId><ArticleId IdType="pmc">PMC6085463</ArticleId><ArticleId IdType="pubmed">30123182</ArticleId></ArticleIdList></Reference><Reference><Citation>Monnot GC, Martinez-Usatorre A, Lanitis E, Lopes SF, Cheng WC, Ho PC, et al. . miR-155 overexpression in OT-1 CD8+ T cells improves anti-tumor activity against low-affinity tumor antigen. Mol Ther Oncolytics. (2020) 16:111–23. doi: 10.1016/j.omto.2019.12.008, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omto.2019.12.008</ArticleId><ArticleId IdType="pmc">PMC6994712</ArticleId><ArticleId IdType="pubmed">32021906</ArticleId></ArticleIdList></Reference><Reference><Citation>Valastyan S, Weinberg RA. Roles for microRNAs in the regulation of cell adhesion molecules. J Cell Sci. (2011) 124:999–1006. doi: 10.1242/jcs.081513, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.081513</ArticleId><ArticleId IdType="pmc">PMC3056602</ArticleId><ArticleId IdType="pubmed">21402873</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Y, Li F, Shi J, Li S, Cai J, Jiang Y. MiR-146a regulates inflammatory infiltration by macrophages in polymyositis/dermatomyositis by targeting TRAF6 and affecting IL-17/ICAM-1 pathway. Cell Physiol Biochem. (2016) 40:486–98. doi: 10.1159/000452563, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000452563</ArticleId><ArticleId IdType="pubmed">27889748</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassif-Lerner R, Zloto K, Rubin N, Asraf K, Doolman R, Paret G, et al. . miR-155: a potential biomarker for predicting mortality in COVID-19 patients. J Pers Med. (2022) 12:324. doi: 10.3390/jpm12020324, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm12020324</ArticleId><ArticleId IdType="pmc">PMC8877479</ArticleId><ArticleId IdType="pubmed">35207812</ArticleId></ArticleIdList></Reference><Reference><Citation>Nachtigall PG, Dias MC, Carvalho RF, Martins C, Pinhal D. MicroRNA-499 expression distinctively correlates to target genes sox6 and rod1 profiles to resolve the skeletal muscle phenotype in Nile tilapia. PLoS One. (2015) 10:e0119804. doi: 10.1371/journal.pone.0119804, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0119804</ArticleId><ArticleId IdType="pmc">PMC4368118</ArticleId><ArticleId IdType="pubmed">25793727</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou C, Hu C, Wang B, Fan S, Jin W. Curcumin suppresses cell proliferation, migration, and invasion through modulating miR-21-5p/SOX6 axis in hepatocellular carcinoma. Cancer Biother Radiopharm. (2020) 35:267–274. doi: 10.1089/cbr.2020.3734, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/cbr.2020.3734</ArticleId><ArticleId IdType="pubmed">32757994</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, Huang S, Liu X, Zhang Y, Wei S, Hu X. miR-155: an important role in inflammation response. J Immunol Res. (2022) 2022:1–13. doi: 10.1155/2022/7437281</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/7437281</ArticleId><ArticleId IdType="pmc">PMC9007653</ArticleId><ArticleId IdType="pubmed">35434143</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, Wang S, Yong Z, Zhang X, Wang X, You P. Effect of miR-499-5p/SOX6 axis on atrial fibrosis in rats with atrial fibrillation. Open Med. (2023) 18:20230654. doi: 10.1515/med-2023-0654, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/med-2023-0654</ArticleId><ArticleId IdType="pmc">PMC10183722</ArticleId><ArticleId IdType="pubmed">37197357</ArticleId></ArticleIdList></Reference><Reference><Citation>Costinean S, Sandhu SK, Pedersen IM, Tili E, Trotta R, Perrotti D, et al. . Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. Blood. (2009) 114:1374–82. doi: 10.1182/blood-2009-05-220814, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-05-220814</ArticleId><ArticleId IdType="pmc">PMC2727407</ArticleId><ArticleId IdType="pubmed">19520806</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Connell RM, Chaudhuri AA, Rao DS, Baltimore D. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci USA. (2009) 106:7113–8. doi: 10.1073/pnas.0902636106, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0902636106</ArticleId><ArticleId IdType="pmc">PMC2678424</ArticleId><ArticleId IdType="pubmed">19359473</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadidi S, Antignano F, Hughes MR, Wang SK, Snyder K, Sammis GM, et al. . Myeloid cell-specific expression of Ship1 regulates IL-12 production and immunity to helminth infection. Mucosal Immunol. (2012) 5:535–43. doi: 10.1038/mi.2012.29, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mi.2012.29</ArticleId><ArticleId IdType="pubmed">22535180</ArticleId></ArticleIdList></Reference><Reference><Citation>Carow B, Ye X, Gavier-Widén D, Bhuju S, Oehlmann W, Singh M, et al. . Silencing suppressor of cytokine signaling-1 (SOCS1) in macrophages improves Mycobacterium tuberculosis control in an interferon-gamma (IFN-gamma)-dependent manner. J Biol Chem. (2011) 286:26873–87. doi: 10.1074/jbc.M111.238287, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.238287</ArticleId><ArticleId IdType="pmc">PMC3143647</ArticleId><ArticleId IdType="pubmed">21622562</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghafouri-Fard S, Shoorei H, Taheri M. Non-coding RNAs participate in the ischemia-reperfusion injury. Biomed Pharmacother. (2020) 129:110419. doi: 10.1016/j.biopha.2020.110419</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2020.110419</ArticleId><ArticleId IdType="pubmed">32563988</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DW, Futami M, Carroll M, Feng Y, Wang Z, Fernandez M, et al. . Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155. Oncogene. (2012) 31:4085–94. doi: 10.1038/onc.2011.579, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2011.579</ArticleId><ArticleId IdType="pubmed">22249254</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue H, Hua LM, Guo M, Luo JM. SHIP1 is targeted by miR-155 in acute myeloid leukemia. Oncol Rep. (2014) 32:2253–9. doi: 10.3892/or.2014.3435, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2014.3435</ArticleId><ArticleId IdType="pubmed">25175984</ArticleId></ArticleIdList></Reference><Reference><Citation>Preiser JC. Oxidative stress. JPEN J Parenter Enteral Nutr. (2012) 36:147–54. doi: 10.1177/0148607111434963</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0148607111434963</ArticleId><ArticleId IdType="pubmed">22301329</ArticleId></ArticleIdList></Reference><Reference><Citation>Arisan ED, Dart A, Grant GH, Arisan S, Cuhadaroglu S, Lange S, et al. . The prediction of miRNAs in SARS-CoV-2 genomes: hsa-miR databases identify 7 key miRs linked to host responses and virus pathogenicity-related KEGG pathways significant for comorbidities. Viruses. (2020) 12:614. doi: 10.3390/v12060614, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12060614</ArticleId><ArticleId IdType="pmc">PMC7354481</ArticleId><ArticleId IdType="pubmed">32512929</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr Clin Res Rev. (2020) 14:247–50. doi: 10.1016/j.dsx.2020.03.013, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.03.013</ArticleId><ArticleId IdType="pmc">PMC7102662</ArticleId><ArticleId IdType="pubmed">32247212</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg A, Seeliger B, Derda AA, Xiao K, Gietz A, Scherf K, et al. . Circulating cardiovascular microRNAs in critically ill COVID-19 patients. Eur J Heart Fail. (2021) 23:468–75. doi: 10.1002/ejhf.2096</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.2096</ArticleId><ArticleId IdType="pmc">PMC8014268</ArticleId><ArticleId IdType="pubmed">33421274</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X-H, Li J-L, Li X-Y, Wang S-X, Jiao Z-H, Li S-Q, et al. . miR-208a in cardiac hypertrophy and remodeling. Front Cardiovasc Med. (2021) 8:773314. doi: 10.3389/fcvm.2021.773314, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.773314</ArticleId><ArticleId IdType="pmc">PMC8695683</ArticleId><ArticleId IdType="pubmed">34957257</ArticleId></ArticleIdList></Reference><Reference><Citation>Eyileten C, Wicik Z, Simoes SN, Martins-Jr DC, Klos K, Wlodarczyk W, et al. . Thrombosis-related circulating miR-16-5p is associated with disease severity in patients hospitalised for COVID-19. RNA Biol. (2022) 19:963–79. doi: 10.1080/15476286.2022.2100629, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15476286.2022.2100629</ArticleId><ArticleId IdType="pmc">PMC9361765</ArticleId><ArticleId IdType="pubmed">35938548</ArticleId></ArticleIdList></Reference><Reference><Citation>Gambardella J, Kansakar U, Sardu C, Messina V, Jankauskas SS, Marfella R, et al. . Exosomal miR-145 and miR-885 regulate thrombosis in COVID-19. J Pharmacol Exp Ther. (2023) 384:109–15. doi: 10.1124/jpet.122.001209, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.122.001209</ArticleId><ArticleId IdType="pmc">PMC9827505</ArticleId><ArticleId IdType="pubmed">35772782</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai X, Bian Z. MicroRNA-21 is a versatile regulator and potential treatment target in central nervous system disorders. Front Mol Neurosci. (2022) 15:842288. doi: 10.3389/fnmol.2022.842288, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2022.842288</ArticleId><ArticleId IdType="pmc">PMC8841607</ArticleId><ArticleId IdType="pubmed">35173580</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra R, Banerjea AC. SARS-CoV-2 spike targets USP33-IRF9 axis via exosomal miR-148a to activate human microglia. Front Immunol. (2021) 12:656700. doi: 10.3389/fimmu.2021.656700, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.656700</ArticleId><ArticleId IdType="pmc">PMC8079643</ArticleId><ArticleId IdType="pubmed">33936086</ArticleId></ArticleIdList></Reference><Reference><Citation>Peleg Y, Kudose S, D’Agati V, Siddall E, Ahmad S, Nickolas T, et al. . Acute kidney injury due to collapsing glomerulopathy following COVID-19 infection. Kidney Int Rep. (2020) 5:940–5. doi: 10.1016/j.ekir.2020.04.017, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2020.04.017</ArticleId><ArticleId IdType="pmc">PMC7186120</ArticleId><ArticleId IdType="pubmed">32346659</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H, Kong L, Zhou S, Cui W, Xu F, Luo M, et al. . The role of microRNAs in diabetic nephropathy. J Diabetes Res. (2014) 2014:1–12. doi: 10.1155/2014/920134, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/920134</ArticleId><ArticleId IdType="pmc">PMC4165734</ArticleId><ArticleId IdType="pubmed">25258717</ArticleId></ArticleIdList></Reference><Reference><Citation>Arghiani N, Nissan T, Matin MM. Role of microRNAs in COVID-19 with implications for therapeutics. Biomed Pharmacother. (2021) 144:112247. doi: 10.1016/j.biopha.2021.112247, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2021.112247</ArticleId><ArticleId IdType="pmc">PMC8463393</ArticleId><ArticleId IdType="pubmed">34601190</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen H, Fang K, Guo H, Wang G. High glucose-induced apoptosis in human kidney cells was alleviated by miR-15b-5p mimics. Biol Pharm Bull. (2019) 42:758–63. doi: 10.1248/bpb.b18-00951, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/bpb.b18-00951</ArticleId><ArticleId IdType="pubmed">30842352</ArticleId></ArticleIdList></Reference><Reference><Citation>Khatami A, Taghizadieh M, Sadri Nahand J, Karimzadeh M, Kiani SJ, Khanaliha K, et al. . Evaluation of microRNA expression pattern (miR-28, miR-181a, miR-34a, and miR-31) in patients with COVID-19 admitted to ICU and diabetic COVID-19 patients. Intervirology. (2023) 66:63–76. doi: 10.1159/000529985, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000529985</ArticleId><ArticleId IdType="pmc">PMC10308556</ArticleId><ArticleId IdType="pubmed">36882006</ArticleId></ArticleIdList></Reference><Reference><Citation>Fomison-Nurse I, Saw EEL, Gandhi S, Munasinghe PE, Van Hout I, Williams MJA, et al. . Diabetes induces the activation of pro-ageing miR-34a in the heart, but has differential effects on cardiomyocytes and cardiac progenitor cells. Cell Death Differ. (2018) 25:1336–49. doi: 10.1038/s41418-017-0047-6, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-017-0047-6</ArticleId><ArticleId IdType="pmc">PMC6030067</ArticleId><ArticleId IdType="pubmed">29302057</ArticleId></ArticleIdList></Reference><Reference><Citation>Alimohamadi Y, Sepandi M, Taghdir M, Hosamirudsari H. Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. J Prev Med Hyg. (2020) 61:E304–12. doi: 10.15167/2421-4248/jpmh2020.61.3.1530, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.15167/2421-4248/jpmh2020.61.3.1530</ArticleId><ArticleId IdType="pmc">PMC7595075</ArticleId><ArticleId IdType="pubmed">33150219</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig AM. Chronic COVID syndrome: need for an appropriate medical terminology for long-COVID and COVID long-haulers. J Med Virol. (2021) 93:2555–6. doi: 10.1002/jmv.26624, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26624</ArticleId><ArticleId IdType="pubmed">33095459</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto MD, Downs CA, Huang Y, El-Azab SA, Ramrakhiani NS, Barisano A, et al. . A distinct symptom pattern emerges for COVID-19 long-haul: a nationwide study. Sci Rep. (2022) 12:15905. doi: 10.1038/s41598-022-20214-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-20214-7</ArticleId><ArticleId IdType="pmc">PMC9508141</ArticleId><ArticleId IdType="pubmed">36151129</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. COVID-19: what do we know about “long COVID”? BMJ. (2020) 370:m2815. doi: 10.1136/bmj.m2815</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m2815</ArticleId><ArticleId IdType="pubmed">32665317</ArticleId></ArticleIdList></Reference><Reference><Citation>Maucher D, Schmidt B, Schumann J. Loss of endothelial barrier function in the inflammatory setting: indication for a cytokine-mediated post-transcriptional mechanism by virtue of upregulation of miRNAs miR-29a-3p, miR-29b-3p, and miR-155-5p. Cells. (2021) 10:2843. doi: 10.3390/cells10112843, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10112843</ArticleId><ArticleId IdType="pmc">PMC8616298</ArticleId><ArticleId IdType="pubmed">34831066</ArticleId></ArticleIdList></Reference><Reference><Citation>Demongeot J, Seligmann H. SARS-CoV-2 and miRNA-like inhibition power. Med Hypotheses. (2020) 144:110245. doi: 10.1016/j.mehy.2020.110245, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.110245</ArticleId><ArticleId IdType="pmc">PMC7471724</ArticleId><ArticleId IdType="pubmed">33254550</ArticleId></ArticleIdList></Reference><Reference><Citation>Visacri MB, Nicoletti AS, Pincinato EC, Loren P, Saavedra N, Saavedra K, et al. . Role of miRNAs as biomarkers of COVID-19: a scoping review of the status and future directions for research in this field. Biomark Med. (2021) 15:1785–95. doi: 10.2217/bmm-2021-0348, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/bmm-2021-0348</ArticleId><ArticleId IdType="pmc">PMC8601154</ArticleId><ArticleId IdType="pubmed">34784802</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Hu X, Li L, Li JH. Differential microRNA expression in the peripheral blood from human patients with COVID-19. J Clin Lab Anal. (2020) 34:e23590. doi: 10.1002/jcla.23590, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcla.23590</ArticleId><ArticleId IdType="pmc">PMC7536972</ArticleId><ArticleId IdType="pubmed">32960473</ArticleId></ArticleIdList></Reference><Reference><Citation>Das R, Sinnarasan VSP, Paul D, Venkatesan A. Correction: a machine learning approach to identify potential miRNA-gene regulatory network contributing to the pathogenesis of SARS-CoV-2 infection. Biochem Genet. (2023) 62:1007. doi: 10.1007/s10528-023-10511-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10528-023-10511-9</ArticleId><ArticleId IdType="pubmed">37668831</ArticleId></ArticleIdList></Reference><Reference><Citation>Smail SW, Babaei E, Amin K. Hematological, inflammatory, coagulation, and oxidative/antioxidant biomarkers as predictors for severity and mortality in COVID-19: a prospective cohort-study. Int J Gen Med. (2023) 16:565–80. doi: 10.2147/IJGM.S402206</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJGM.S402206</ArticleId><ArticleId IdType="pmc">PMC9942608</ArticleId><ArticleId IdType="pubmed">36824986</ArticleId></ArticleIdList></Reference><Reference><Citation>Smail SW, Babaei E, Amin K. Demographic, clinical and genetic factors associated with COVID-19 disease susceptibility and mortality in a Kurdish population. Ann Saudi Med. (2023) 43:125–42. doi: 10.5144/0256-4947.2023.125, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.5144/0256-4947.2023.125</ArticleId><ArticleId IdType="pmc">PMC10317494</ArticleId><ArticleId IdType="pubmed">37270678</ArticleId></ArticleIdList></Reference><Reference><Citation>Smail SW, Babaei E, Amin K, Abdulahad WH. Serum IL-23, IL-10, and TNF-α predict in-hospital mortality in COVID-19 patients. Front Immunol. (2023) 14:1145840. doi: 10.3389/fimmu.2023.1145840, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1145840</ArticleId><ArticleId IdType="pmc">PMC10239952</ArticleId><ArticleId IdType="pubmed">37283736</ArticleId></ArticleIdList></Reference><Reference><Citation>Smail SW, Babaei E, Amin K. Ct, IL-18 polymorphism, and laboratory biomarkers for predicting chemosensory dysfunctions and mortality in COVID-19. Future Sci OA. (2023) 9:FSO838. doi: 10.2144/fsoa-2022-0082</Citation><ArticleIdList><ArticleId IdType="doi">10.2144/fsoa-2022-0082</ArticleId><ArticleId IdType="pmc">PMC10005086</ArticleId><ArticleId IdType="pubmed">36999046</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernández-Pato A, Virseda-Berdices A, Resino S, Ryan P, Martínez-González O, Pérez-García F, et al. . Plasma miRNA profile at COVID-19 onset predicts severity status and mortality. Emerg Microbes Infect. (2022) 11:676–88. doi: 10.1080/22221751.2022.2038021, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2038021</ArticleId><ArticleId IdType="pmc">PMC8890551</ArticleId><ArticleId IdType="pubmed">35130828</ArticleId></ArticleIdList></Reference><Reference><Citation>Matarese A, Gambardella J, Sardu C, Santulli G. miR-98 regulates TMPRSS2 expression in human endothelial cells: key implications for COVID-19. Biomedicines. (2020) 8:462. doi: 10.3390/biomedicines8110462, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines8110462</ArticleId><ArticleId IdType="pmc">PMC7693865</ArticleId><ArticleId IdType="pubmed">33143053</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson JC, Kealy D, James SR, Plowman T, Newling K, Jagger C, et al. . Integrated miRNA/cytokine/chemokine profiling reveals severity-associated step changes and principal correlates of fatality in COVID-19. iScience. (2022) 25:103672. doi: 10.1016/j.isci.2021.103672, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2021.103672</ArticleId><ArticleId IdType="pmc">PMC8686203</ArticleId><ArticleId IdType="pubmed">34957382</ArticleId></ArticleIdList></Reference><Reference><Citation>Song L, Liu H, Gao S, Jiang W, Huang W. Cellular microRNAs inhibit replication of the H1N1 influenza a virus in infected cells. J Virol. (2010) 84:8849–60. doi: 10.1128/JVI.00456-10, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00456-10</ArticleId><ArticleId IdType="pmc">PMC2919005</ArticleId><ArticleId IdType="pubmed">20554777</ArticleId></ArticleIdList></Reference><Reference><Citation>de Gonzalo-Calvo D, Benítez ID, Pinilla L, Carratalá A, Moncusí-Moix A, Gort-Paniello C, et al. . Circulating microRNA profiles predict the severity of COVID-19 in hospitalized patients. Transl Res. (2021) 236:147–59. doi: 10.1016/j.trsl.2021.05.004, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2021.05.004</ArticleId><ArticleId IdType="pmc">PMC8149473</ArticleId><ArticleId IdType="pubmed">34048985</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Rius A, Lopez S, Martinez-Perez A, Souto JC, Soria JM. Identification of a plasma MicroRNA profile associated with venous thrombosis. Arterioscler Thromb Vasc Biol. (2020) 40:1392–9. doi: 10.1161/ATVBAHA.120.314092, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.120.314092</ArticleId><ArticleId IdType="pubmed">32160777</ArticleId></ArticleIdList></Reference><Reference><Citation>de Gonzalo-Calvo D, Molinero M, Benítez ID, Perez-Pons M, García-Mateo N, Ortega A, et al. . A blood microRNA classifier for the prediction of ICU mortality in COVID-19 patients: a multicenter validation study. Respir Res. (2023) 24:159. doi: 10.1186/s12931-023-02462-x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-023-02462-x</ArticleId><ArticleId IdType="pmc">PMC10276486</ArticleId><ArticleId IdType="pubmed">37328754</ArticleId></ArticleIdList></Reference><Reference><Citation>Recchiuti A, Patruno S, Mattoscio D, Isopi E, Pomilio A, Lamolinara A, et al. . Resolvin D1 and D2 reduce SARS-CoV-2-induced inflammatory responses in cystic fibrosis macrophages. FASEB J. (2021) 35:e21441. doi: 10.1096/fj.202001952R, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.202001952R</ArticleId><ArticleId IdType="pmc">PMC8250053</ArticleId><ArticleId IdType="pubmed">33749902</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang H, Gao Y, Li Z, Miao Y, Huang Z, Liu X, et al. . The noncoding and coding transcriptional landscape of the peripheral immune response in patients with COVID-19. Clin Transl Med. (2020) 10:e200. doi: 10.1002/ctm2.200, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ctm2.200</ArticleId><ArticleId IdType="pmc">PMC7548099</ArticleId><ArticleId IdType="pubmed">33135345</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyler E, Mosbauer K, Franke V, Diag A, Gottula LT, Arsie R, et al. . Transcriptomic profiling of SARS-CoV-2 infected human cell lines identifies HSP90 as target for COVID-19 therapy. iScience. (2021) 24:102151. doi: 10.1016/j.isci.2021.102151, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2021.102151</ArticleId><ArticleId IdType="pmc">PMC7866843</ArticleId><ArticleId IdType="pubmed">33585804</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Z, Wang J, Wang Z, Sun Y, Wu J, Zhang Y, et al. . A virus-derived microRNA-like small RNA serves as a serum biomarker to prioritize the COVID-19 patients at high risk of developing severe disease. Cell Discov. (2021) 7:48. doi: 10.1038/s41421-021-00289-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-021-00289-8</ArticleId><ArticleId IdType="pmc">PMC8257610</ArticleId><ArticleId IdType="pubmed">34226530</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald JT, Enguita FJ, Taylor D, Griffin RJ, Priebe W, Emmett MR, et al. . Role of miR-2392 in driving SARS-CoV-2 infection. Cell Rep. (2021) 37:109839. doi: 10.1016/j.celrep.2021.109839, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109839</ArticleId><ArticleId IdType="pmc">PMC8481092</ArticleId><ArticleId IdType="pubmed">34624208</ArticleId></ArticleIdList></Reference><Reference><Citation>Giuliani A, Matacchione G, Ramini D, Di Rosa M, Bonfigli AR, Sabbatinelli J, et al. . Circulating miR-320b and miR-483-5p levels are associated with COVID-19 in-hospital mortality. Mech Ageing Dev. (2022) 202:111636. doi: 10.1016/j.mad.2022.111636, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mad.2022.111636</ArticleId><ArticleId IdType="pmc">PMC8809668</ArticleId><ArticleId IdType="pubmed">35122770</ArticleId></ArticleIdList></Reference><Reference><Citation>Smail SW, Saeed M, Alkasalias T, Khudhur ZO, Younus DA, Rajab MF, et al. . Inflammation, immunity and potential target therapy of SARS-COV-2: a total scale analysis review. Food Chem Toxicol. (2021) 150:112087. doi: 10.1016/j.fct.2021.112087, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fct.2021.112087</ArticleId><ArticleId IdType="pmc">PMC7905385</ArticleId><ArticleId IdType="pubmed">33640537</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed JQ, Maulud SQ, Dhawan M, Priyanka, Choudhary OP, Jalal PJ, et al. . MicroRNAs in the development of potential therapeutic targets against COVID-19: a narrative review. J Infect Public Health. (2022) 15:788–99. doi: 10.1016/j.jiph.2022.06.012, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2022.06.012</ArticleId><ArticleId IdType="pmc">PMC9221922</ArticleId><ArticleId IdType="pubmed">35751930</ArticleId></ArticleIdList></Reference><Reference><Citation>Ying H, Ebrahimi M, Keivan M, Khoshnam SE, Salahi S, Farzaneh M. miRNAs; a novel strategy for the treatment of COVID-19. Cell Biol Int. (2021) 45:2045–53. doi: 10.1002/cbin.11653, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbin.11653</ArticleId><ArticleId IdType="pmc">PMC8426984</ArticleId><ArticleId IdType="pubmed">34180562</ArticleId></ArticleIdList></Reference><Reference><Citation>Lener T, Gimona M, Aigner L, Borger V, Buzas E, Camussi G, et al. . Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. J Extracell Vesicles. (2015) 4:30087. doi: 10.3402/jev.v4.30087, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3402/jev.v4.30087</ArticleId><ArticleId IdType="pmc">PMC4698466</ArticleId><ArticleId IdType="pubmed">26725829</ArticleId></ArticleIdList></Reference><Reference><Citation>Casado-Diaz A, Quesada-Gomez JM, Dorado G. Extracellular vesicles derived from mesenchymal stem cells (MSC) in regenerative medicine: applications in skin wound healing. Front Bioeng Biotechnol. (2020) 8:146. doi: 10.3389/fbioe.2020.00146, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fbioe.2020.00146</ArticleId><ArticleId IdType="pmc">PMC7062641</ArticleId><ArticleId IdType="pubmed">32195233</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbatinelli J, Giuliani A, Matacchione G, Latini S, Laprovitera N, Pomponio G, et al. . Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients. Mech Ageing Dev. (2021) 193:111413. doi: 10.1016/j.mad.2020.111413, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mad.2020.111413</ArticleId><ArticleId IdType="pmc">PMC7722494</ArticleId><ArticleId IdType="pubmed">33307107</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert DW, Lambert LA, Clarke NE, Hooper NM, Porter KE, Turner AJ. Angiotensin-converting enzyme 2 is subject to post-transcriptional regulation by miR-421. Clin Sci. (2014) 127:243–9. doi: 10.1042/CS20130420, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20130420</ArticleId><ArticleId IdType="pubmed">24564768</ArticleId></ArticleIdList></Reference><Reference><Citation>Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. . miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. (2005) 102:13944–9. doi: 10.1073/pnas.0506654102, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0506654102</ArticleId><ArticleId IdType="pmc">PMC1236577</ArticleId><ArticleId IdType="pubmed">16166262</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Chu Q, Wang H. MicroRNA-16 regulates lipopolysaccharide-induced inflammatory factor expression by targeting TLR4 in normal human bronchial epithelial cells. Exp Ther Med. (2021) 22:982. doi: 10.3892/etm.2021.10414, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2021.10414</ArticleId><ArticleId IdType="pmc">PMC8311244</ArticleId><ArticleId IdType="pubmed">34345264</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum C, Loiselle J, Ahmed N, Shaw TA, Toudic C, Pezacki JP. MicroRNA mimics or inhibitors as antiviral therapeutic approaches against COVID-19. Drugs. (2021) 81:517–31. doi: 10.1007/s40265-021-01474-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-021-01474-5</ArticleId><ArticleId IdType="pmc">PMC7910799</ArticleId><ArticleId IdType="pubmed">33638807</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JH, Choi Y, Lim CW, Park JM, Yu SH, Kim Y, et al. . Potential therapeutic effect of microRNAs in extracellular vesicles from mesenchymal stem cells against SARS-CoV-2. Cells. (2021) 10:2393. doi: 10.3390/cells10092393, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10092393</ArticleId><ArticleId IdType="pmc">PMC8465096</ArticleId><ArticleId IdType="pubmed">34572043</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, He Y, Wang X, Lu F, Gao J. Adipose-derived mesenchymal stem cells exhibit tumor tropism and promote tumorsphere formation of breast cancer cells. Oncol Rep. (2019) 41:2126–36. doi: 10.3892/or.2019.7018, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2019.7018</ArticleId><ArticleId IdType="pmc">PMC6412463</ArticleId><ArticleId IdType="pubmed">30816504</ArticleId></ArticleIdList></Reference><Reference><Citation>Keikha R, Hashemi-Shahri SM, Jebali A. The relative expression of miR-31, miR-29, miR-126, and miR-17 and their mRNA targets in the serum of COVID-19 patients with different grades during hospitalization. Eur J Med Res. (2021) 26:75. doi: 10.1186/s40001-021-00544-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40001-021-00544-4</ArticleId><ArticleId IdType="pmc">PMC8276226</ArticleId><ArticleId IdType="pubmed">34256840</ArticleId></ArticleIdList></Reference><Reference><Citation>Cory H, Passarelli S, Szeto J, Tamez M, Mattei J. The role of polyphenols in human health and food systems: a mini-review. Front Nutr. (2018) 5:87. doi: 10.3389/fnut.2018.00087, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2018.00087</ArticleId><ArticleId IdType="pmc">PMC6160559</ArticleId><ArticleId IdType="pubmed">30298133</ArticleId></ArticleIdList></Reference><Reference><Citation>Montenegro-Landívar MF, Tapia-Quirós P, Vecino X, Reig M, Valderrama C, Granados M, et al. . Polyphenols and their potential role to fight viral diseases: an overview. Sci Total Environ. (2021) 801:149719. doi: 10.1016/j.scitotenv.2021.149719, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scitotenv.2021.149719</ArticleId><ArticleId IdType="pmc">PMC8373592</ArticleId><ArticleId IdType="pubmed">34438146</ArticleId></ArticleIdList></Reference><Reference><Citation>Iddir M, Brito A, Dingeo G, Fernandez Del Campo SS, Samouda H, La Frano MR, et al. . Strengthening the immune system and reducing inflammation and oxidative stress through diet and nutrition: considerations during the COVID-19 crisis. Nutrients. (2020) 12:1562. doi: 10.3390/nu12061562, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12061562</ArticleId><ArticleId IdType="pmc">PMC7352291</ArticleId><ArticleId IdType="pubmed">32471251</ArticleId></ArticleIdList></Reference><Reference><Citation>Milenkovic D, Ruskovska T, Rodriguez-Mateos A, Heiss C. Polyphenols could prevent SARS-CoV-2 infection by modulating the expression of miRNAs in the host cells. Aging Dis. (2021) 12:1169–82. doi: 10.14336/AD.2021.0223, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.14336/AD.2021.0223</ArticleId><ArticleId IdType="pmc">PMC8279534</ArticleId><ArticleId IdType="pubmed">34341700</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y-P, Hsieh Y-S, Cheng M-H, Shen C-F, Shen C-J, Cheng C-M. Using microRNA arrays as a tool to evaluate COVID-19 vaccine efficacy. Vaccine. (2022) 10:1681. doi: 10.3390/vaccines10101681, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10101681</ArticleId><ArticleId IdType="pmc">PMC9607069</ArticleId><ArticleId IdType="pubmed">36298546</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyashita Y, Yoshida T, Takagi Y, Tsukamoto H, Takashima K, Kouwaki T, et al. . Circulating extracellular vesicle microRNAs associated with adverse reactions, proinflammatory cytokine, and antibody production after COVID-19 vaccination. npj Vaccines. (2022) 7:16. doi: 10.1038/s41541-022-00439-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-022-00439-3</ArticleId><ArticleId IdType="pmc">PMC8826357</ArticleId><ArticleId IdType="pubmed">35136071</ArticleId></ArticleIdList></Reference><Reference><Citation>Capistrano KJ, Richner J, Schwartz J, Mukherjee SK, Shukla D, Naqvi AR. Host microRNAs exhibit differential propensity to interact with SARS-CoV-2 and variants of concern. Biochim Biophys Acta Mol basis Dis. (2023) 1869:166612. doi: 10.1016/j.bbadis.2022.166612, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2022.166612</ArticleId><ArticleId IdType="pmc">PMC9721271</ArticleId><ArticleId IdType="pubmed">36481486</ArticleId></ArticleIdList></Reference><Reference><Citation>Keikha R, Hashemi-Shahri SM, Jebali A. The miRNA neuroinflammatory biomarkers in COVID-19 patients with different severity of illness. Neurologia. (2023) 38:e41–51. doi: 10.1016/j.nrl.2021.06.005, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nrl.2021.06.005</ArticleId><ArticleId IdType="pmc">PMC10278372</ArticleId><ArticleId IdType="pubmed">37344097</ArticleId></ArticleIdList></Reference><Reference><Citation>Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA. (2006) 103:12481–6. doi: 10.1073/pnas.0605298103, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0605298103</ArticleId><ArticleId IdType="pmc">PMC1567904</ArticleId><ArticleId IdType="pubmed">16885212</ArticleId></ArticleIdList></Reference><Reference><Citation>Starikova I, Jamaly S, Sorrentino A, Blondal T, Latysheva N, Sovershaev M, et al. . Differential expression of plasma miRNAs in patients with unprovoked venous thromboembolism and healthy control individuals. Thromb Res. (2015) 136:566–72. doi: 10.1016/j.thromres.2015.07.005, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2015.07.005</ArticleId><ArticleId IdType="pubmed">26235746</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Koh P, Winbanks C, Coughlan MT, McClelland A, Watson A, et al. . miR-200a prevents renal fibrogenesis through repression of TGF-β2 expression. Diabetes. (2011) 60:280–7. doi: 10.2337/db10-0892, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db10-0892</ArticleId><ArticleId IdType="pmc">PMC3012183</ArticleId><ArticleId IdType="pubmed">20952520</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Jha JC, Hagiwara S, McClelland AD, Jandeleit-Dahm K, Thomas MC, et al. . Transforming growth factor-beta1-mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b. Kidney Int. (2014) 85:352–61. doi: 10.1038/ki.2013.372, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2013.372</ArticleId><ArticleId IdType="pubmed">24088962</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato M, Wang L, Putta S, Wang M, Yuan H, Sun G, et al. . Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-beta-induced collagen expression in kidney cells. J Biol Chem. (2010) 285:34004–15. doi: 10.1074/jbc.M110.165027, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.165027</ArticleId><ArticleId IdType="pmc">PMC2962500</ArticleId><ArticleId IdType="pubmed">20713358</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh M, Minami Y, Takahashi Y, Tabuchi T, Nakamura M. Expression of microRNA-208 is associated with adverse clinical outcomes in human dilated cardiomyopathy. J Card Fail. (2010) 16:404–10. doi: 10.1016/j.cardfail.2010.01.002, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardfail.2010.01.002</ArticleId><ArticleId IdType="pubmed">20447577</ArticleId></ArticleIdList></Reference><Reference><Citation>Das R, Sinnarasan VSP, Paul D, Venkatesan A. A machine learning approach to identify potential miRNA-gene regulatory network contributing to the pathogenesis of SARS-CoV-2 infection. Biochem Genet. (2023) 62:987–1006. doi: 10.1007/s10528-023-10458-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10528-023-10458-x</ArticleId><ArticleId IdType="pubmed">37515735</ArticleId></ArticleIdList></Reference><Reference><Citation>Centa A, Fonseca AS, da Silva Ferreira SG, Azevedo MLV, de Paula CBV, Nagashima S, et al. . Deregulated miRNA expression is associated with endothelial dysfunction in post-mortem lung biopsies of COVID-19 patients. Am J Physiol Lung Cell Mol Physiol. (2021) 320:L405–12. doi: 10.1152/ajplung.00457.2020, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00457.2020</ArticleId><ArticleId IdType="pmc">PMC7938642</ArticleId><ArticleId IdType="pubmed">33651636</ArticleId></ArticleIdList></Reference><Reference><Citation>Haroun RA, Osman WH, Amin RE, Hassan AK, Abo-Shanab WS, Eessa AM. Circulating plasma miR-155 is a potential biomarker for the detection of SARS-CoV-2 infection. Pathology. (2022) 54:104–10. doi: 10.1016/j.pathol.2021.09.006, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pathol.2021.09.006</ArticleId><ArticleId IdType="pmc">PMC8570980</ArticleId><ArticleId IdType="pubmed">34838331</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu D, Chatterjee S, Xiao K, Riedel I, Wang Y, Foo R, et al. . MicroRNAs targeting the SARS-CoV-2 entry receptor ACE2 in cardiomyocytes. J Mol Cell Cardiol. (2020) 148:46–9. doi: 10.1016/j.yjmcc.2020.08.017, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2020.08.017</ArticleId><ArticleId IdType="pmc">PMC7470794</ArticleId><ArticleId IdType="pubmed">32891636</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Du J, Yu X, Xu J, Huang F, Li X, et al. . miRNA-200c-3p is crucial in acute respiratory distress syndrome. Cell Discov. (2017) 3:17021. doi: 10.1038/celldisc.2017.21, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/celldisc.2017.21</ArticleId><ArticleId IdType="pmc">PMC5485385</ArticleId><ArticleId IdType="pubmed">28690868</ArticleId></ArticleIdList></Reference><Reference><Citation>Seto AG, Beatty X, Lynch JM, Hermreck M, Tetzlaff M, Duvic M, et al. . Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. Br J Haematol. (2018) 183:428–44. doi: 10.1111/bjh.15547, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.15547</ArticleId><ArticleId IdType="pubmed">30125933</ArticleId></ArticleIdList></Reference><Reference><Citation>Kianmehr A, Faraoni I, Kucuk O, Mahrooz A. Epigenetic alterations and genetic variations of angiotensin-converting enzyme 2 (ACE2) as a functional receptor for SARS-CoV-2: potential clinical implications. Eur J Clin Microbiol Infect Dis. (2021) 40:1587–98. doi: 10.1007/s10096-021-04264-9, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-021-04264-9</ArticleId><ArticleId IdType="pmc">PMC8091148</ArticleId><ArticleId IdType="pubmed">33939044</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardin LT, Xiao N. miRNAs: the key regulator of COVID-19 disease. Int J Cell Biol. (2022) 2022:1645366. doi: 10.1155/2022/1645366</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/1645366</ArticleId><ArticleId IdType="pmc">PMC9637033</ArticleId><ArticleId IdType="pubmed">36345541</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>